Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study
Flibanserin (FLB) was approved by FDA for the treatment of pre-menopausal female hypoactive sexual desire disorder (HSDD). FLB suffers from low oral bioavailability (33%) which might be due to hepatic first-pass metabolism in addition to its poor aqueous solubility. The sublingual route could be a p...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Llyfr |
| Cyhoeddwyd: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
| Pynciau: | |
| Mynediad Ar-lein: | Connect to this object online. |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Rhyngrwyd
Connect to this object online.3rd Floor Main Library
| Rhif Galw: |
A1234.567 |
|---|---|
| Copi 1 | Ar gael |